Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Sara M. Tolaney, MD, MPH, on Immunotherapy for Breast Cancer: Moving Into Early-Stage Disease

Posted: Tuesday, February 25, 2020

Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institute, discusses how immunotherapy has been more successful in other tumor types than breast cancer and whether immune checkpoint inhibition is likely to be most effective in the neoadjuvant setting.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.